Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.37 |
| ▸ | GHSR | Q92847 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12536264 | 1.00 | CHRM5 (0.53) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL10042370 | 1.00 | CHRM5 (0.53) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL15242460 | 0.98 | CHRM5 (0.50) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL24890774 | 0.91 | CHRM5 (0.50) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL19083160 | 0.91 | CHRM5 (0.50) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL15242464 | 0.89 | CHRM5 (0.47) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL23205756 | 0.89 | CHRM5 (0.47) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL19782222 | 0.85 | CHRM5 (0.50) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL19768956 | 0.85 | CHRM5 (0.50) | CHRM5ADRA2CKCNH2CCR2ACHE | |
| SCHEMBL24832951 | 0.85 | KCNH2 (0.44) | CHRM5ADRA2CKCNH2CCR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119692-B2 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | ANTXR2, ABAT, BAX | CHRM5 4238/4885ADRA2C 1146/4885KCNH2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.